In the last 12 months, insiders at TACTILE SYSTEMS TECHNOLOGY INC ($TCMD) filed 80 transactions with the SEC: 0 open-market purchases totaling $0 and 32 sales totaling $3,048,970. Net insider sentiment: net selling.
TACTILE SYSTEMS TECHNOLOGY INC operates in the Surgical & medical instruments & apparatus industry (Industrial Applications and Services sector).
Most Active Insiders
- Dodd Sheri Louise (Chief Executive Officer) — 11 transactions totaling $876,251
- Burns Kristie (Sr. VP Mktg & Clinical Affairs) — 21 transactions totaling $716,295
- REUVERS DANIEL L. (Director) — 5 transactions totaling $560,997
- Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER) — 7 transactions totaling $379,024
- REUVERS DANIEL L. (President and CEO) — 7 transactions totaling $272,935
View all SEC Filings for TACTILE SYSTEMS TECHNOLOGY INC (TCMD).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Pearson Andrea | Not found | A | Common Stock | 852 | $0.00 | 852.0000 | 23,295,328 | 9999.99% | 0.00% |
| Feb. 24, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S | Common Stock | 7701 | $28.94 | 134,819.0000 | 23,295,328 | 5.40% | 0.03% |
| Feb. 24, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 6246 | $28.94 | 82,581.0000 | 23,295,328 | 7.03% | 0.03% |
| Feb. 24, 2026 | Dodd Sheri Louise | Chief Executive Officer | S | Common Stock | 10993 | $28.94 | 243,885.0000 | 23,295,328 | 4.31% | 0.05% |
| Feb. 23, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S | Common Stock | 196 | $28.69 | 142,520.0000 | 23,295,328 | 0.14% | 0.00% |
| Feb. 20, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A | Common Stock | 15575 | $0.00 | 148,038.0000 | 23,295,328 | 11.76% | 0.07% |
| Feb. 20, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A | Common Stock | 6765 | $0.00 | 132,463.0000 | 23,295,328 | 5.38% | 0.03% |
| Feb. 20, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A | Common Stock | 3579 | $0.00 | 125,698.0000 | 23,295,328 | 2.93% | 0.02% |
| Feb. 20, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 4058 | $0.00 | 86,143.0000 | 23,295,328 | 4.94% | 0.02% |
| Feb. 20, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 3490 | $0.00 | 82,085.0000 | 23,295,328 | 4.44% | 0.01% |
| Feb. 23, 2026 | Dodd Sheri Louise | Chief Executive Officer | S | Common Stock | 537 | $28.69 | 254,878.0000 | 23,295,328 | 0.21% | 0.00% |
| Feb. 23, 2026 | Dodd Sheri Louise | Chief Executive Officer | S | Common Stock | 14703 | $28.28 | 255,415.0000 | 23,295,328 | 5.44% | 0.06% |
| Feb. 20, 2026 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 28216 | $0.00 | 270,118.0000 | 23,295,328 | 11.66% | 0.12% |
| Feb. 20, 2026 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 19751 | $0.00 | 241,902.0000 | 23,295,328 | 8.89% | 0.08% |
| Feb. 23, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S | Common Stock | 5322 | $28.28 | 142,716.0000 | 23,295,328 | 3.60% | 0.02% |
| Feb. 23, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 160 | $28.69 | 88,827.0000 | 23,295,328 | 0.18% | 0.00% |
| Feb. 23, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 4279 | $28.28 | 88,987.0000 | 23,295,328 | 4.59% | 0.02% |
| Feb. 20, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 7123 | $0.00 | 93,266.0000 | 23,295,328 | 8.27% | 0.03% |
| Feb. 19, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 6194 | $0.00 | 78,595.0000 | 23,295,328 | 8.56% | 0.03% |
| Feb. 19, 2026 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 48672 | $0.00 | 222,151.0000 | 23,295,328 | 28.06% | 0.21% |
| Feb. 19, 2026 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A | Common Stock | 23008 | $0.00 | 122,119.0000 | 23,295,328 | 23.21% | 0.10% |
| Jan. 2, 2026 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 5139 | $28.85 | 72,401.0000 | 23,295,328 | 6.63% | 0.02% |
| Aug. 8, 2025 | Dodd Sheri Louise | Chief Executive Officer | S | Common Stock | 7762 | $12.36 | 173,479.0000 | 23,237,671 | 4.28% | 0.03% |
| May 12, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | S | Common Stock | 2921 | $9.94 | 99,111.0000 | 23,710,643 | 2.86% | 0.01% |
| May 8, 2025 | Dodd Sheri Louise | Chief Executive Officer | S | Common Stock | 3149 | $9.83 | 181,241.0000 | 23,710,643 | 1.71% | 0.01% |
| May 7, 2025 | Washington Boyd Vindell | Director | A | Common Stock | 16078 | $0.00 | 35,247.0000 | 23,710,643 | 83.88% | 0.07% |
| May 7, 2025 | BURKE WILLIAM W | Director | A | Common Stock | 16078 | $0.00 | 51,820.0000 | 23,710,643 | 44.98% | 0.07% |
| May 8, 2025 | BURKE WILLIAM W | Director | S | Common Stock | 3300 | $9.67 | 48,520.0000 | 23,710,643 | 6.37% | 0.01% |
| May 7, 2025 | Asbury Valerie L. | Director | A | Common Stock | 16078 | $0.00 | 48,822.0000 | 23,710,643 | 49.10% | 0.07% |
| May 7, 2025 | Huggenberger Raymond | Director | A | Common Stock | 16078 | $0.00 | 56,320.0000 | 23,710,643 | 39.95% | 0.07% |
| May 7, 2025 | King Laura G. | Director | A | Common Stock | 16078 | $0.00 | 19,048.0000 | 23,710,643 | 541.35% | 0.07% |
| May 7, 2025 | Shafer David Brent | Director | A | Common Stock | 16078 | $0.00 | 48,822.0000 | 23,710,643 | 49.10% | 0.07% |
| May 7, 2025 | Volkart Carmen B | Director | A | Common Stock | 16078 | $0.00 | 37,698.0000 | 23,710,643 | 74.37% | 0.07% |
| March 11, 2025 | REUVERS DANIEL L. | Director | G | Common Stock | 68162 | $0.00 | 214,604.0000 | 24,138,244 | 46.55% | 0.28% |
| March 11, 2025 | REUVERS DANIEL L. | Director | G | Common Stock | 68162 | $0.00 | 214,604.0000 | 24,138,244 | 24.11% | 0.28% |
| Feb. 25, 2025 | REUVERS DANIEL L. | Director | S | Common Stock | 28338 | $14.18 | 214,604.0000 | 24,138,244 | 11.66% | 0.12% |
| Feb. 25, 2025 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 6468 | $14.40 | 77,540.0000 | 24,138,244 | 7.70% | 0.03% |
| Feb. 25, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | S | Common Stock | 2066 | $14.51 | 102,032.0000 | 24,138,244 | 1.98% | 0.01% |
| Feb. 20, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | A | Common Stock | 36248 | $0.00 | 107,876.0000 | 24,138,244 | 50.61% | 0.15% |
| Feb. 20, 2025 | King Laura G. | Director | A | Common Stock | 2970 | $0.00 | 2,970.0000 | 24,138,244 | 9999.99% | 0.01% |
| Feb. 20, 2025 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 20108 | $0.00 | 118,721.0000 | 24,138,244 | 20.39% | 0.08% |
| Feb. 20, 2025 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 65669 | $0.00 | 184,390.0000 | 24,138,244 | 55.31% | 0.27% |
| Feb. 20, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | A | Common Stock | 3446 | $0.00 | 64,741.0000 | 24,138,244 | 5.62% | 0.01% |
| Feb. 20, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | A | Common Stock | 6887 | $0.00 | 71,628.0000 | 24,138,244 | 10.64% | 0.03% |
| Feb. 24, 2025 | Birkemeyer Elaine M. | Chief Financial Officer | S | Common Stock | 3778 | $14.70 | 104,098.0000 | 24,138,244 | 3.50% | 0.02% |
| Feb. 20, 2025 | REUVERS DANIEL L. | Director | A | Common Stock | 15853 | $0.00 | 253,880.0000 | 24,138,244 | 6.66% | 0.07% |
| Feb. 24, 2025 | REUVERS DANIEL L. | Director | S | Common Stock | 10938 | $14.55 | 242,942.0000 | 24,138,244 | 4.31% | 0.05% |
| Feb. 20, 2025 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 3359 | $0.00 | 68,128.0000 | 24,138,244 | 5.19% | 0.01% |
| Feb. 20, 2025 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 4131 | $0.00 | 72,259.0000 | 24,138,244 | 6.06% | 0.02% |
| Feb. 20, 2025 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 16579 | $0.00 | 88,838.0000 | 24,138,244 | 22.94% | 0.07% |
| Feb. 24, 2025 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 4830 | $14.65 | 84,008.0000 | 24,138,244 | 5.44% | 0.02% |
| Aug. 12, 2024 | Ferstler Sherri Lee | Senior VP, Sales | S | Common Stock | 1550 | $13.07 | 38,764.0000 | 24,099,047 | 3.84% | 0.01% |
| Aug. 7, 2024 | Dodd Sheri Louise | Chief Executive Officer | A | Common Stock | 64959 | $0.00 | 98,613.0000 | 24,099,047 | 193.02% | 0.27% |
| May 16, 2024 | Birkemeyer Elaine M. | Chief Financial Officer | S | Common Stock | 3041 | $13.68 | 61,295.0000 | 23,665,829 | 4.73% | 0.01% |
| May 8, 2024 | BURKE WILLIAM W | Director | A | Common Stock | 10469 | $0.00 | 35,742.0000 | 23,665,829 | 41.42% | 0.04% |
| May 8, 2024 | Asbury Valerie L. | Director | A | Common Stock | 10469 | $0.00 | 32,744.0000 | 23,665,829 | 47.00% | 0.04% |
| May 8, 2024 | Dodd Sheri Louise | Director | A | Common Stock | 10469 | $0.00 | 33,654.0000 | 23,665,829 | 45.15% | 0.04% |
| May 8, 2024 | Huggenberger Raymond | Director | A | Common Stock | 10469 | $0.00 | 40,242.0000 | 23,665,829 | 35.16% | 0.04% |
| May 8, 2024 | Shafer David Brent | Director | A | Common Stock | 10469 | $0.00 | 32,744.0000 | 23,665,829 | 47.00% | 0.04% |
| May 8, 2024 | Volkart Carmen B | Director | A | Common Stock | 10469 | $0.00 | 21,620.0000 | 23,665,829 | 93.88% | 0.04% |
| May 8, 2024 | Washington Boyd Vindell | Director | A | Common Stock | 10469 | $0.00 | 19,169.0000 | 23,665,829 | 120.33% | 0.04% |
| May 8, 2024 | BURKE WILLIAM W | Director | S | Common Stock | 2500 | $14.06 | 25,273.0000 | 23,665,829 | 9.00% | 0.01% |
| May 6, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 815 | $14.37 | 62,574.0000 | 23,665,829 | 1.29% | 0.00% |
| Feb. 27, 2024 | REUVERS DANIEL L. | President and CEO | S | Common Stock | 4689 | $15.60 | 239,423.0000 | 23,176,169 | 1.92% | 0.02% |
| Feb. 29, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 243 | $15.25 | 63,389.0000 | 23,176,169 | 0.38% | 0.00% |
| Feb. 27, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 1091 | $15.58 | 63,632.0000 | 23,176,169 | 1.69% | 0.00% |
| Feb. 29, 2024 | REUVERS DANIEL L. | President and CEO | S | Common Stock | 1396 | $15.25 | 238,027.0000 | 23,176,169 | 0.58% | 0.01% |
| Feb. 23, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 2249 | $14.80 | 53,765.0000 | 23,176,169 | 4.02% | 0.01% |
| Feb. 24, 2024 | REUVERS DANIEL L. | President and CEO | A | Common Stock | 13100 | $0.00 | 250,351.0000 | 23,176,169 | 5.52% | 0.06% |
| Feb. 24, 2024 | REUVERS DANIEL L. | President and CEO | A | Common Stock | 44930 | $0.00 | 237,251.0000 | 23,176,169 | 23.36% | 0.19% |
| Feb. 23, 2024 | REUVERS DANIEL L. | President and CEO | S | Common Stock | 5378 | $14.85 | 192,321.0000 | 23,176,169 | 2.72% | 0.02% |
| Feb. 26, 2024 | REUVERS DANIEL L. | President and CEO | S | Common Stock | 6239 | $15.81 | 244,112.0000 | 23,176,169 | 2.49% | 0.03% |
| Feb. 24, 2024 | Birkemeyer Elaine M. | Chief Financial Officer | A | Common Stock | 2848 | $0.00 | 64,336.0000 | 23,176,169 | 4.63% | 0.01% |
| Feb. 26, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S | Common Stock | 2015 | $15.91 | 63,512.0000 | 23,176,169 | 3.08% | 0.01% |
| Feb. 24, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 2776 | $0.00 | 65,527.0000 | 23,176,169 | 4.42% | 0.01% |
| Feb. 24, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 8986 | $0.00 | 62,751.0000 | 23,176,169 | 16.71% | 0.04% |
| Feb. 21, 2024 | Birkemeyer Elaine M. | Chief Financial Officer | A | Common Stock | 32420 | $0.00 | 61,488.0000 | 23,176,169 | 111.53% | 0.14% |
| Feb. 21, 2024 | REUVERS DANIEL L. | President and CEO | A | Common Stock | 72046 | $0.00 | 197,699.0000 | 23,176,169 | 57.34% | 0.31% |
| Feb. 21, 2024 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A | Common Stock | 19452 | $0.00 | 56,014.0000 | 23,176,169 | 53.20% | 0.08% |
| Feb. 21, 2024 | Ferstler Sherri Lee | Senior VP, Sales | A | Common Stock | 21613 | $0.00 | 40,314.0000 | 23,176,169 | 115.57% | 0.09% |